Nuclear medicine vendor ADAC Laboratories will highlight its MolecularCoincidence Detection (MCD) technique, which enables high-energypositron imaging to be conducted on gamma cameras without theuse of the heavy collimators employed in 511-KeV imaging.
Nuclear medicine vendor ADAC Laboratories will highlight its MolecularCoincidence Detection (MCD) technique, which enables high-energypositron imaging to be conducted on gamma cameras without theuse of the heavy collimators employed in 511-KeV imaging.
ADAC, of Milpitas, CA, debuted MCD at the Society of NuclearMedicine meeting in Minneapolis earlier this year (SCAN 6/21/95).By employing the digital architecture of ADAC's Epic technology,MCD uses electronic collimation to measure coincidents, whichoccur when photons are released at 180° angles due to theannihilation of an electron by a positron. MCD achieves an intrinsicresolution of 4 mm, compared to about 10-mm resolution in 511-KeVimaging. ADAC is awaiting 510(k) clearance for the technique.
ADAC's Solus and Cardio gamma cameras will also make their RSNAdebut. Introduced at the SNM meeting, Solus is a fixed-angle 180°dual-head camera, while Cardio is a 90° dual-head for dedicatedcardiac imaging. The new products are designed to target specificapplications at a lower price point than ADAC's premium Vertexcamera.
The third part of ADAC's new product triangle is Vantage, thevendor's attenuation-correction protocol for cardiac imaging,which received Food and Drug Administration clearance in April(SCAN 5/10/95).
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.